As China readies to deliberate a draft of its first IP overhaul in over a decade, the government has recently passed two laws and one regulation that could help shield biopharma companies from IP loss.
Mark Cohen, head of the Asia IP project
Read the full 422 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD